Villa Edward, Stier Matthew, Donboli Kianoush, Chapman Christopher Grant, Siddiqui Uzma D, Waxman Irving
University of Chicago Medical Center, Center for Endoscopic Research and Therapeutics (CERT), Chicago, Illinois, United States.
Endosc Int Open. 2020 Jun;8(6):E724-E732. doi: 10.1055/a-1132-5323. Epub 2020 May 25.
Colonic lesions may not be amenable to conventional endoscopic mucosal resection (EMR) due to previous manipulation, submucosal invasion, or lesion flatness. In 2018, we described Dissection-enabled Scaffold Assisted Resection (DeSCAR) to be safe for the endoscopic resection of non-lifting or residual colonic lesions 1 In this study, we expand our original cohort to describe our expanded experience with patients undergoing DeSCAR and assess the efficacy, safety, and feasibility of DeSCAR for endoscopic resection of non-lifting or residual colonic lesions. We retrospectively reviewed 57 patients from 2015-2019 who underwent DeSCAR for colonic lesions with incomplete lifting and/or previous manipulation. Cases were reviewed for location, prior manipulation, rates of successful resection, adverse events, and endoscopic follow up to assess for residual lesions. Fifty-seven lesions underwent DeSCAR. Of the patients, 51 % were female, and average patient age was 69 years. Lesions were located in the cecum (n = 16), right colon (n = 27), left colon (n = 10), and rectum (n = 4). Average lesion size was 27.7 mm. Previous manipulation occurred in 54 cases (72 % biopsy, 44 % resection attempt, 18 % intralesional tattoo). The technical success rate for resection of non-lifting lesions was 98 %. There were two delayed bleeding episodes (one required endoscopic intervention) and one small perforation (managed by endoscopic hemoclip closure). Endoscopic follow up was available in 31 patients (54 %) with no residual adenoma in 28 patients (90 % of those surveilled). Our expanded experience with DeSCAR demonstrates high safety, feasibility, and effectiveness for the endoscopic management of non-lifting or residual colonic lesions.
由于先前的操作、黏膜下浸润或病变平坦,结肠病变可能不适于传统的内镜黏膜切除术(EMR)。2018年,我们描述了支架辅助可剥离切除术(DeSCAR),该方法对于非抬举性或残留性结肠病变的内镜切除是安全的。在本研究中,我们扩大了原始队列,以描述我们在接受DeSCAR治疗的患者中的更多经验,并评估DeSCAR用于非抬举性或残留性结肠病变内镜切除的疗效、安全性和可行性。
我们回顾性分析了2015年至2019年间57例接受DeSCAR治疗的结肠病变患者,这些病变存在抬举不完全和/或先前有过操作。对病例进行了位置、先前操作、成功切除率、不良事件以及内镜随访以评估残留病变等方面的审查。
57个病变接受了DeSCAR治疗。患者中51%为女性,平均年龄为69岁。病变位于盲肠(n = 16)、右结肠(n = 27)、左结肠(n = 10)和直肠(n = 4)。平均病变大小为27.7mm。54例(72%)有先前操作(活检,44%;切除尝试,44%;病变内纹身,18%)。非抬举性病变的切除技术成功率为98%。有2例迟发性出血(1例需要内镜干预)和1例小穿孔(通过内镜钛夹闭合处理)。31例患者(54%)接受了内镜随访,其中28例患者(接受监测患者的90%)无残留腺瘤。
我们在DeSCAR方面的更多经验表明,对于非抬举性或残留性结肠病变的内镜治疗,其具有高度的安全性、可行性和有效性。